News As Streeting threatens no deal, talks on drug levy collapse The UK government's threat to withdraw from negotiations on rebates paid by industry on NHS medicines has been followed by the collapse of talks.
Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
News UK is becoming an 'outlier' for pharma, hitting investment UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.